TuisSHTDF • OTCMKTS
add
Sinopharm Group Co Ltd
Vorige sluiting
$2,49
Jaarwisseling
$1,97 - $2,95
Markkapitalisasie
62,92 mjd HKD
Gemiddelde volume
97,00
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
HKG
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (CNY) | Jun. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 147,36 mjd | -5,19% |
Bedryfskoste | 6,78 mjd | 4,18% |
Netto inkomste | 1,85 mjd | -26,34% |
Netto winsgrens | 1,26 | -22,22% |
Wins per aandeel | — | — |
EBITDA | 4,76 mjd | -25,05% |
Effektiewe belastingkoers | 22,34% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (CNY) | Jun. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 43,33 mjd | 26,05% |
Totale bates | 429,58 mjd | 2,85% |
Totale aanspreeklikheid | 307,15 mjd | 0,84% |
Totale ekwiteit | 122,43 mjd | — |
Uitstaande aandele | 3,12 mjd | — |
Prys om te bespreek | 0,10 | — |
Opbrengs op bates | 2,44% | — |
Opbrengs op kapitaal | 4,69% | — |
Kontantvloei
Netto kontantverandering
| (CNY) | Jun. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | 1,85 mjd | -26,34% |
Kontant van bedrywe | -20,50 mjd | -678,47% |
Kontant van beleggings | -519,26 m | -167,92% |
Kontant van finansiering | 10,78 mjd | 5 713,58% |
Netto kontantverandering | -10,24 mjd | -512,13% |
Beskikbare kontantvloei | 2,71 mjd | 108,45% |
Meer oor
Sinopharm Group Co., Ltd. is a Chinese pharmaceutical company. The parent company of Sinopharm Group was Sinopharm Industrial Investment, a 51–49 joint venture of state-owned enterprise China National Pharmaceutical Group and civilian-run enterprise Fosun Pharmaceutical.
Its H shares were listed on the Hong Kong Stock Exchange in 2009, with its IPO price of HK$16 per share. Sinopharm Group's subsidiary Sinopharm CNMC and Sinopharm Accord served as the A share counterpart of the company. However, the A share of Sinopharm Group itself was unlisted.
Sinopharm Group was ranked 829th in 2016 Forbes Global 2000 list. Wikipedia
Gestig
2003
Webwerf
Werknemers
113 635
